venBio Global Strategic Fund III L.P. 13D and 13G filings for Elevation Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-08-08 9:05 pm Sale |
2024-08-08 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 2,031,920 3.400% |
-505,851 (-19.93%) |
Filing |
| 2023-06-15 4:30 pm Purchase |
2023-06-13 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 2,537,771 6.100% |
671,432 (+35.98%) |
Filing |
| 2022-09-26 4:21 pm Unchanged |
2021-06-29 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 1,866,339 8.000% |
0 (Unchanged) |
Filing |
| 2022-05-27 5:26 pm Sale |
2022-05-25 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 1,866,339 8.030% |
-741,828 (-28.44%) |
Filing |
| 2021-07-09 4:01 pm Purchase |
2021-06-29 | 13D | Elevation Oncology, Inc. ELEV |
venBio Global Strategic Fund III L.P. | 2,608,167 11.430% |
2,608,167 (New Position) |
Filing |